查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456979

特发性肺纤维化治疗的全球市场 – 2024 年至 2029 年预测

Global Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年特发性肺纤维化治疗市值为34.59亿美元，复合年增长率为11.87%，到2029年市场规模将达75.85亿美元。

特发性肺纤维化是一种严重的肺部疾病。特发性肺纤维化是一种肺部疾病，透过在肺内形成疤痕组织来损害肺组织。疤痕组织在肺部边缘形成并扩散到肺部中心。在这种病理下，正常组织会被肺部内形成的疤痕组织所取代。肺部形成的疤痕组织厚重而粗糙，导致呼吸沉重而粗糙。特发性肺纤维化肺部疾病会降低肺部的供氧能力，使疾病更加严重且严重。就特发性肺纤维化而言，尚未确定具体原因，但吸烟和接触污染有毒空气是导致此疾病的主要因素。世界各地报告的这种疾病的发生率不断增加，增加了这种疾病的风险和严重程度。缺乏对特发性肺纤维化的治疗方法也增加了肺部疾病的危险因子和死亡率。

不断增加的污染率和吸烟成瘾的趋势为全球医疗市场中特发性肺纤维化治疗的市场成长提供了潜力。针对特发性肺纤维化的适当药物和治疗方法的缺乏也推动了特发性肺纤维化治疗市场的成长。由于盛行率不断上升、医学研究的进步和创新治疗方法，全球特发性肺纤维化（IPF）治疗市场预计将成长。该市场的特点是不断致力于解决未满足的医疗需求、引入新的治疗方案和改善患者的治疗效果。

市场驱动因素：

  • 吸烟率上升和空气污染预计将推动市场成长

对于特发性肺纤维化，没有记录确切的原因或原因。人们吸烟习惯的增加被认为是特发性肺纤维化的主要原因之一。吸烟对人们的自然呼吸能力和肺部健康产生负面影响。肺活量和肺部健康下降使您更容易患肺部疾病。根据世界卫生组织 (WHO) 的报告，每 100 名男性中约有 15 名吸烟，约 15.3%。就女性吸烟习惯而言，每 100 人中有 13 人是吸烟者。据美国卫生与公众服务部称，美国 25 至 44 岁和 45 至 64 岁年龄层的吸烟率最高。

空气污染是工业化造成的主要影响之一。工厂和生产车间产生的大量废气占空气污染的很大一部分。汽车碳排放的增加也导致空气污染加剧。空气污染加剧会导致肺部疾病，降低人们的肺部健康，使人们更容易患有特发性肺纤维化等严重肺部疾病。吸烟率的增加和空气污染为特发性肺纤维化治疗市场的成长提供了潜力。

  • 老化率上升将推动市场成长。

老化速度加快也是推动肺纤维化治疗市场成长的关键因素。老化社会或60至65岁以上的人更容易患特发性肺纤维化等疾病。特发性肺纤维化或肺部疾病也已成为导致老年人死亡的致命且严重的疾病。合适药物的缺乏和特发性肺纤维化病例的增加正在推动特发性肺纤维化治疗市场的成长。人口老化正在增加医疗资源的使用，并增加对专业护理的需求，特别是对于特发性肺纤维化等慢性疾病。医学诊断的进步和认识的提高可能会实现更早、更准确的诊断，并增加对适当治疗的需求。认识到特发性肺纤维化是一个重大的健康问题，可能会刺激创新治疗方法的发现和商业化的研究和开发。

预计亚太地区将占据主要市场占有率

亚太地区特发性肺纤维化治疗市场正在经历更大的成长。亚太地区肺病患者和特发性肺纤维化患者数量的增加正在推动亚洲特发性肺纤维化治疗市场的成长。药物治疗领域的大规模投资也促进了市场成长。在亚太地区，人们对特发性肺纤维化（IPF）的认识正在迅速提高，对治疗的需求也增加。该地区人口正在老化，这种疾病在老年人中更为常见，从而促进了疾病的传播。改善卫生基础设施和获得先进医疗保健可以改善诊断和治疗。增加研发投资可能会带来新的治疗方法并增加市场占有率。政府措施、卫生政策和报销计画可以加速先进治疗方法的采用。製药公司、研究机构和医疗保健提供者之间的合作可以促进有效 IPF治疗方法的开发和商业化。患者权益团体也可以在提高意识和影响政策方面发挥作用。

主要进展

  • 2023 年 1 月 - Lotus Pharmaceutical 的尼达尼布胶囊（勃林格殷格翰 OFEV® 的学名药药）的简化新药认证申请 (ANDA) 获得美国FDA 的临时核准。
  • 2022 年 5 月 - 山德士宣布在美国推出第一个学名药Pirfenidone，用于治疗特发性肺纤维化 (IPF)，这是一种罕见的进行性疾病，主要影响50 岁以上的成年人。该学名药是第一个与 Genentech 的 Esbriet 完全可互换的学名药，目前可透过专科药房购买，并为符合条件的患者提供 0 美元自付额计划。 IPF 是一种罕见的进行性疾病，无法治疗方法，影响着大约 14 万名美国。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球特发性肺纤维化治疗市场：依治疗类型

  • 介绍
  • 药物类别
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 氧气疗法
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 肺移植
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 其他的
    • 市场机会趋势
    • 成长前景
    • 地域盈利

第六章全球特发性肺纤维化治疗市场：依药物类型

  • 介绍
  • Pirfenidone
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 尼达尼布
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第七章全球特发性肺纤维化治疗市场：依应用分类

  • 介绍
  • 医院
    • 市场机会趋势
    • 成长前景
    • 地理收益
  • 诊所
    • 市场机会和趋势
    • 成长前景
    • 地理收益

第八章全球特发性肺纤维化治疗市场：按地区

  • 介绍
  • 北美洲
    • 按治疗类型
    • 依药物类型
    • 按用途
    • 按国家/地区
  • 南美洲
    • 按治疗类型
    • 依药物类型
    • 按用途
    • 按国家/地区
  • 欧洲
    • 按治疗类型
    • 依药物类型
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 按治疗类型
    • 依药物类型
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 按治疗类型
    • 依药物类型
    • 按用途
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Boehringer Ingelheim GMBH
  • Bristol-Myers Squibb Company
  • Biogen
  • Cipla
  • Hoffman-La Roche AG
  • Fibrogen, Inc.
  • Galapagos NV
  • Medicinova, Inc.
  • Novartis AG
  • Prometic Life sciences Inc.
简介目录
Product Code: KSI061612250

The Idiopathic pulmonary fibrosis market is evaluated at US$3.459 billion for the year 2022 growing at a CAGR of 11.87% reaching the market size of US$7.585 billion by the year 2029.

Idiopathic pulmonary fibrosis is a certain type of severe lung disease. Idiopathic pulmonary fibrosis is a lung disease in which the lung tissues are damaged by the formation of scar tissue within the lungs. The scar tissue is formed at the edges of the lungs, and they are spread to the center of the lungs. In this disease condition, normal tissues are replaced by the scar tissues formed in the lungs. The heavy and rough nature of scar tissue formed in the lungs will result in heavy and rough breathing in people. Idiopathic pulmonary fibrosis lung disease will result in the reduction of the oxygen capacity of the lungs, making the disease more severe and critical. A specific cause is not at all identified in the case of idiopathic pulmonary fibrosis, but smoking cigarettes and exposure to polluted and toxic air are major factors leading to the disease. The increasing rate of the disease reported around the globe is raising the risk and criticality of the disease. The fewer treatment methods available for Idiopathic pulmonary fibrosis also increase the risk factor and fatal rate of lung disease.

The increasing pollution rate and rising trend of smoking addiction are giving potential to the market growth of Idiopathic pulmonary fibrosis treatment on the global medical market. The low availability of proper medication and treatment for Idiopathic pulmonary fibrosis is also driving the market growth of global idiopathic pulmonary fibrosis treatment. The global idiopathic pulmonary fibrosis (IPF) treatment market is expected to grow due to increasing prevalence, medical research advancements, and innovative therapies. The market is characterized by ongoing initiatives to address unmet medical needs, introducing novel therapeutic options, and focusing on improving patient outcomes.

MARKET DRIVERS:

  • The rising rate of smoking and air pollution is anticipated to surge the market growth

The exact cause or reasons are not recorded in the case of Idiopathic pulmonary fibrosis lung disease. The increasing smoking habit in people is considered one of the major reasons for the cause of Idiopathic pulmonary fibrosis. Smoking cigarettes adversely affects the natural breathing capacity and lung health of people. The decreased lung capacity and the health of the lungs are making individuals more vulnerable to lung diseases. The reports of the WHO (World Health Organisation) claim that about 15 of every 100 men are cigarette smokers, and it's approximately 15.3%. In the case of smoking habits in women, about 13 of every 100 women are also smokers. The U.S. Department of Health and Human Services states that in America, cigarette smoking is highest among people in the age group 25 to 44 years and 45 to 64 years.

Air pollution is one of the major impacts caused as a result of industrialization. The large emissions from factories and production plants contribute to a major share of atmospheric pollution. The higher rate of carbon emission from automobiles is also leading to rising air pollution in the atmosphere. The increasing air pollution in the atmosphere is also causing lung diseases and declining lung health in people, making them vulnerable to severe lung diseases like idiopathic pulmonary fibrosis. The increased smoking rate and air pollution are giving potential to the market growth of Idiopathic Pulmonary Fibrosis treatment.

  • An increasing rate of an aging population will bolster the growth of the market.

The increasing rate of an aging population is also a significant factor driving the market growth of the pulmonary fibrosis treatment market. The aging population or people above 60 to 65 years of age are more prone to the diseases like idiopathic pulmonary fibrosis. Idiopathic pulmonary Fibrosis and lung diseases are also becoming more fatal and critical in aged people resulting in mortality. The low availability of proper medication and increasing cases of idiopathic pulmonary fibrosis are driving the market growth of the global idiopathic pulmonary fibrosis treatment market. The aging population is increasingly utilizing healthcare resources, leading to a growing demand for specialized care, particularly for chronic diseases like idiopathic pulmonary fibrosis. Advancements in medical diagnostics and increased awareness may increase early and accurate diagnoses, leading to a higher demand for appropriate treatments. This recognition of idiopathic pulmonary fibrosis as a significant health concern may drive research and development efforts to discover and commercialize innovative treatment options.

Asia Pacific region is predicted to hold a significant market share

Asia Pacific region is having more market growth in idiopathic pulmonary fibrosis treatment. The rising number of lung patients and people suffering from Idiopathic Pulmonary Fibrosis in the Asia Pacific region is raising the market growth of idiopathic pulmonary Fibrosis treatment in Asia. The large investments made in the medication sector are also boosting market growth. The Asia Pacific region is experiencing a surge in awareness of idiopathic pulmonary fibrosis (IPF), leading to increased demand for treatments. The region's aging population, which is more common in older individuals, is also contributing to the disease's prevalence. Improvements in healthcare infrastructure and access to advanced medical treatments could improve diagnosis and treatment. Increased investment in research and development could lead to novel therapies and market share growth. Government initiatives, healthcare policies, and reimbursement programs could encourage the adoption of advanced treatments. Collaborations between pharmaceutical companies, research institutions, and healthcare providers could lead to the development and commercialization of effective IPF treatments. Patient advocacy groups can also play a role in raising awareness and influencing policies.

Key Developments:

  • January 2023- Lotus Pharmaceutical has received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, a generic version of Boehringer Ingelheim's OFEV(R). The company plans to launch the generic Nintedanib Capsules at the earliest available opportunity.
  • May 2022- Sandoz has announced the launch of its first generic pirfenidone in the US for treating idiopathic pulmonary fibrosis (IPF), a rare, progressive disease primarily affecting adults over 50. The AB-rated medication is the first fully substitutable equivalent to Genentech's Esbriet and is now available through specialty pharmacies with a $0 co-pay program for eligible patients. IPF is a progressive, rare disease with no cure, affecting approximately 140,000 Americans.

Segmentation

By Treatment Type

  • Drug class
  • Oxygen Therapy
  • Lung Transplant
  • Others

By Drug Type

  • Pirfenidone
  • Nintedanib

By Application

  • Hospital
  • Clinic

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

  • 5.1. Introduction
  • 5.2. Drug class
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Oxygen Therapy
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Lung Transplant
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. Pirfenidone
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Nintedanib
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Hospital
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Clinic
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Treatment Type
    • 8.2.2. By Drug Type
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Treatment Type
    • 8.3.2. By Drug Type
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Treatment Type
    • 8.4.2. By Drug Type
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Treatment Type
    • 8.5.2. By Drug Type
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Treatment Type
    • 8.6.2. By Drug Type
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Boehringer Ingelheim GMBH
  • 10.2. Bristol-Myers Squibb Company
  • 10.3. Biogen
  • 10.4. Cipla
  • 10.5. Hoffman-La Roche AG
  • 10.6. Fibrogen, Inc.
  • 10.7. Galapagos NV
  • 10.8. Medicinova, Inc.
  • 10.9. Novartis AG
  • 10.10. Prometic Life sciences Inc.